Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)

Pancreatic Cancer Stage III Clinical Trial

Official title: Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma

Status Recruiting

Clinical Trial Summary

This study is for patients with locally advanced pancreatic cancer (cancer that involves the local blood vessels so it cannot be removed without cutting major blood vessels) that cannot be treated with surgery. The purpose of this study is to assess the safety and benefit of 6 three week cycles of chemotherapy treatment consisting of gemcitabine, capecitabine and docetaxel (also called 'GTX'). The patients fall into two groups. Group I are those with only venous involvement. Group II patients have arterial involvement and may also have venous involvement. If there is arterial involvement, GTX will be followed by 5 and 1/2 weeks of radiation therapy with gemcitabine and capecitabine. After the chemotherapy and radiation treatment, participants may be able to have surgery to remove any remaining pancreatic cancer.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pancreatic Cancer Stage II
• Pancreatic Cancer Stage III
• Pancreatic Neoplasms

• NCT number: NCT01065870
• Study type: Interventional
• Source: Columbia University
• Contact: Kyung Chu, RN
• Phone: 212-305-9467
• Email: kc2113@columbia.edu
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: December 2009